Aptar Pharma acquires inhaler developer Pulmotree
Aptar Pharma has acquired Munich-based Pulmotree, adding its Kolibri non-propellant liquid inhaler platform to Aptar's respiratory drug-delivery portfolio. The deal follows an exclusive collaboration the two companies began in 2024. Aptar intends to take Kolibri, which is designed for complex molecules including biologics, through clinical evaluation to market launch with pharmaceutical partners.
Why this mattersGives Aptar ownership of a propellant-free liquid inhaler platform for biologics, turning a 2024 collaboration into an in-house respiratory device offer.
- Aptar Pharma has acquired Pulmotree, a Munich-based pulmonary drug delivery company
- The deal adds Pulmotree's Kolibri Non-Propellant Liquid Inhaler (NPLI) platform to Aptar Pharma's respiratory device portfolio
- Aptar and Pulmotree had an exclusive collaboration agreement in place since 2024
- Kolibri uses a breath-triggered vibrating mesh aerosolisation engine designed for targeted lung deposition of complex molecules, including biologics
- Aptar plans to combine Kolibri with Nanopharm formulation, Noble human-factors and Aptar Digital Health services
Sources
Aptar